Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 22, 10, 41, 2 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 11 and 2 molecules, respectively.

Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction 5
Human Papillomavirus (HPV) Associated Cancer - Overview 6
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 7
Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 19
Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 28
Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 52
Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 275
Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 278
Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 279
Appendix 291

List Of Tables


Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abion Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Abivax SA, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antiva Biosciences Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cue Biopharma Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Denceptor Therapeutics Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corp, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Hookipa Biotech AG, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunomic Therapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by IMV Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Iovance Biotherapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Juno Therapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune LLC, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Merck & Co Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Merck KGaA, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by NeoImmuneTech Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oxford Vacmedix UK Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Pathovax LLC, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by PDS Biotechnology Corp, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Rottapharm Biotech Srl, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences Inc, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2018
Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shuttle Pharmaceuticals Inc, H2 2018

List Of Figures


Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018

Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2018, provides an overview

USD 2000 View Report

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It

USD 3500 View Report

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2018Human Papillomavirus Protein E6 (E6) - The Human Papillomavirus (HPV) E6 protein is one of oncoproteins encoded by the virus. It

USD 3500 View Report

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2018

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2018Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available